338 results on '"Stephans, K.L."'
Search Results
2. Liver Stereotactic Body Radiation Therapy (SBRT) to Downstage Patients with Hepatocellular Carcinoma prior to Liver Transplant
3. Single-Fraction Lung SBRT Outcomes for Tumors ≥ 3cm
4. Patient-Free Simulation: Analysis of Hospitalized Patients Treated without CT Simulation
5. Using kV Triggered Imaging and Liver Dome Position to Reduce the Dosimetric Error Caused by Breath Hold Variability for Liver Stereotactic Body Radiation Therapy
6. Change in Quality of Life after Stereotactic Body Radiation Therapy (SBRT) on a Prospective Trial of Peripheral Stage I or II Non-Small Cell Lung Cancer Predicts Survival
7. Cardiac and Great Vessel Toxicity with Single Fraction Stereotactic Body Radiotherapy in Early-Stage Lung Cancer
8. Recursive Partitioning Analysis to Define Prognostic Groups Using a Large Single Institution Experience of Multimodality Radiation Therapy for Bladder Cancer
9. Optimizing Lung SBRT Dose while Accounting for Histology Ensures Optimal Local Control for Inoperable Stage I Non-Small Cell Lung Cancer: Can Higher Biologically Equivalent Dose Overcome Size and SUV?
10. Impact of Time-to-Treatment on Lung SBRT Outcomes: Histology Matters!
11. Local Control and Safety of Abdominopelvic Stereotactic Body Radiotherapy (SBRT) Following Bevacizumab for Oligometastatic Gynecologic Malignancies
12. Transcriptomic Features of Cribriform and Intraductal Carcinoma of the Prostate
13. The Impact of KRAS Mutation and PD-L1 Status on Outcomes of Definitive Stereotactic Body Radiation (SBRT) for Stage I Non-Small Cell Lung Cancer (NSCLC)
14. Toxicity Profile for Connective Tissue Disease Patients Treated with Lung Stereotactic Body Radiation Therapy (SBRT)
15. Prostate Cancer Screening Disparities in Persons Experiencing Homelessness
16. Stereotactic Body Radiation Therapy for Sarcoma Pulmonary Metastases: Outcomes and Fractionation Schedules
17. Patterns and Predictors of Distant Failure After Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Retrospective Multi-Institutional Analysis
18. Comparison of SBRT for Oligometastatic Colorectal Cancer by Site: Lung vs. Liver
19. Identification of Putative Gene-Target Modulators of Radiosensitivity in Bladder Cancer Cell Lines (BlaCCL)
20. Stereotactic Body Radiotherapy for the Treatment of Oligometastatic Gynecological Malignancy in the Abdomen and Pelvis: A Single-Institution Experience
21. Ten-Year Experience in Implementing Single-Fraction Lung SBRT for Medically Inoperable Early Stage Lung Cancer
22. Feasibility of Ultrasound-Based Intra-Fraction Motion Monitoring for Prostate Stereotactic Body Radiation Therapy
23. Using 4D-CBCT for Lung Cancer SBRT Patients to Detect Tumor Motion Variations
24. 125I Interstitial Brachytherapy with or without Androgen Deprivation Therapy among Unfavorable Risk Prostate Cancer
25. Impact of Prior Y90 Dosimetry on Toxicity and Outcomes Following SBRT for Hepatocellular Carcinoma
26. Transcriptomic and Mutational Analyses Identify Biological Processes Correlated with Bladder Cancer Cell Line (BlaCCL) Radiation Response
27. Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 323 Prospectively Treated Patients
28. A Common Polymorphism in 3β-hydroxysteroid Dehydrogenase Promotes Resistance to Radiotherapy
29. Outcomes after SBRT for Inoperable Early Stage Lung Cancers Arising in Organ Transplant Patients
30. Evaluating the 2018 NCCN Classification System for Intermediate-risk Prostate Cancer Patients Undergoing External-beam Radiation Therapy
31. Monitoring Intra-Fraction Prostate Motion Using Kv Triggered Imaging during SBRT
32. Validation of the 2018 NCCN Prostate Cancer Risk Classification among 2,715 Patients Treated with Low Dose Rate I-125 Brachytherapy
33. Impact of Post-Prostatectomy Prostate Specific Antigen (PSA) Kinetics on Outcomes of Salvage Radiotherapy
34. Impact of Cribriform Pattern 4 and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy
35. Downstaging of Hepatocellular Carcinoma Outside Milan Criteria Using SBRT
36. Ten-Year Outcomes and Toxicity with Moderately Hypofractionated (70 Gy in 28 fractions) Intensity-Modulated Radiation Therapy for Localized Prostate Cancer.
37. Impact of Tumor Location & Dosimetric Predictors for Chest Wall Toxicity in Single Fraction SBRT for Stage I Non-Small Cell Lung Cancer
38. Evaluating Safety and Dosimetry of SBRT following 90Y for Hepatocellular Carcinoma
39. Salvage Stereotactic Body Radiation Therapy for Local Recurrence after Primary Surgical Resection of Early Stage Non-Small Cell Lung Cancer
40. Validation of RTOG 0813 Normal Tissue Constraints for Pulmonary Toxicity for Stereotactic Body Radiation Therapy in Central Non-Small Cell Lung Cancer
41. Anatomically Restricted Dose Escalated SBRT to the Pancreas Effects High Local Control and Rapid and Substantial Pain Relief
42. The Influence of Technical Delivery Factors on Local Control with Stereotactic Body Radiation for Early Stage Non-Small Cell Lung Cancer (e-NSCLC)
43. An Externally Validated Nomogram for Predicting Distant Metastasis after Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: Implications for Adjuvant Systemic Therapy
44. Investigation of Brachial Plexus Dose that Exceeds RTOG Constraints in Apical Lung Tumors Treated by Five Fraction Stereotactic Body Radiation Therapy
45. Outcomes of Stereotactic Body Radiation Therapy Delivered by Gantry-Based Linear Accelerators for Low and Intermediate-Risk Prostate Adenocarcinoma: A Multi-institutional Study
46. Tumor Gene Expression Profiling in Prostate Cancer (PCa) Identifies Molecular Taxonomies Associated with Node Positivity and Quantitative Imaging Features on Multiparametric MRI (mpMRI)
47. Outcomes following Stereotactic Body Radiation Therapy for Patients with Child-Pugh B or C Hepatocellular Carcinoma
48. Effect of Margin Size and Image Guidance Method on Biochemical Failure and Toxicity in Prostate Cancer Treated with IMRT
49. Achieving “Zero PSA” Following Post-Prostatectomy Radiation Therapy for Lymph Node Positive Prostate Cancer in the Ultrasensitive PSA Era
50. Heterogeneous Dose-Escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: Quality of Life and Clinical Outcomes of an Institutional Phase 2 Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.